| abstract |
IT REFERS TO CHROME DERIVATIVES OF FORMULA I, WHERE: R IS HYDROXY, OXO, HALO, CYANE, NITRO, C1-C10 ALKYL OPTIONALLY SUBSTITUTED WITH PHENYL, C1-C10 HALOALKYL, CF3, NR1R1, SR1, OR1, SORE IN OTHERS; R1 IS H, (CH2) d-O- (CH2) dR5, C1-C10 ALKYL OPTIONALLY SUBSTITUTED WITH HYDROXY, HALO, CO2-C1-C4 ALKYL, AMONG OTHERS; d IS 1-3; R2 IS R1, OR1, NR1R1, NHS (O) bPHENYL OPTIONALLY SUBSTITUTED WITH C1-C4 ALKYL, C1-C4 ALCOXY, AMONG OTHERS; R3 IS H, C1-C10 ALKYL, BENZYL, COR2; R4 IS H, C1-C10 ALKYL, C1-C10 ALKYL-PHENYL, C1-C10 ALKYL-PYRIDINE, AMONG OTHERS; R5 IS H O COOH; Ar IS PHENYLUS OPTIONALLY FUSED TO A CYCLOHEXYL, PHENYL, HETEROCYCLE OF 5-6 MEMBERS; X IS O, S (O) b; Y IS HALO, R1, OR1, SR1, CO2R1, NR1R1, S (O) b-PHENYL-CO2R1, PHENYL OPTIONALLY FUSED WITH PHENYL, HETEROCYCLE; a ES 0-5; b IS 0-2; e IS 1-2. PREFERRED COMPOUNDS ARE (2S) -1 - ({[(2R) -6-IODINE-3,4-DIHYDRO-2H-CHROMEN-2-IL] METHYL} AMINO) -3-PHENOXY-2-PROPANOL; (2S) -1- (BENZYL {[(2R) -6-BROMO-3,4-DIHYDRO-2H-CHROMEN-2-IL] METHYL} AMINO) -3-PHENOXY-2-PROPANOL, AMONG OTHERS; IT ALSO REFERS TO A METHOD FOR PREPARATION AND A PHARMACEUTICAL COMPOSITION. THE COMPOUNDS ARE AGONISTS OF THE BETA-3 ADRENERGIC RECEPTOR AND MAY BE USEFUL FOR THE TREATMENT OF DIABETES, GLUCOSE DISORDERS IN FASTING, IMPROVED GLUCOSE TOLERANCE, OBESITY, HYPERTRIGLYCERIDEMIA, HYPERTRIGLYCERIDEMIA, HYPERTRIGLYCERIDEMIA, HYPERTRIGLYCERIDEMIA, HIPERPLASTIC, RELATED PRIORITY EFFECT, EFFECT. |